StockNews.com lowered shares of Iradimed (NASDAQ:IRMD - Free Report) from a strong-buy rating to a buy rating in a research note released on Wednesday.
Iradimed Trading Down 2.0 %
NASDAQ IRMD traded down $1.21 on Wednesday, hitting $60.15. The company's stock had a trading volume of 31,970 shares, compared to its average volume of 36,478. The firm has a market cap of $762.10 million, a P/E ratio of 41.20 and a beta of 0.82. The company's 50-day simple moving average is $56.77 and its 200 day simple moving average is $51.72. Iradimed has a 52-week low of $40.18 and a 52-week high of $63.29.
Insider Transactions at Iradimed
In other news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the transaction, the chief financial officer now owns 4,383 shares of the company's stock, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 37.10% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of IRMD. R Squared Ltd bought a new position in shares of Iradimed in the 4th quarter worth approximately $30,000. US Bancorp DE boosted its holdings in Iradimed by 476.6% in the 4th quarter. US Bancorp DE now owns 617 shares of the medical equipment provider's stock worth $34,000 after buying an additional 510 shares during the period. Huntington National Bank raised its stake in Iradimed by 51.3% during the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider's stock valued at $75,000 after purchasing an additional 504 shares during the period. Gladius Capital Management LP raised its position in shares of Iradimed by 126.6% during the third quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider's stock valued at $87,000 after buying an additional 965 shares during the last quarter. Finally, Quantbot Technologies LP grew its stake in Iradimed by 83.0% during the third quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider's stock valued at $117,000 after acquiring an additional 1,052 shares in the last quarter. Hedge funds and other institutional investors own 92.34% of the company's stock.
Iradimed Company Profile
(
Get Free Report)
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Further Reading
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
